China Drug Delivery Devices Market Outlook 2031
The China drug delivery devices market size was USD XX billion in 2022 and is likely to reach USD XX billion by 2031, expanding at a CAGR of XX% during the forecast period. The growth of the market is attributed to the rising number of technological advancements during the forecast period.
Drugs at the action site cannot reach adequate concentrations to achieve predicted therapeutic outcomes due to poor physicochemical qualities and multi-stage biological barriers in vivo, which can lead to side effects in normal tissues and organs. Drug delivery devices are useful tools for the delivery of a therapeutic agent or drug through a specific route of administration.
China's population is ageing, and chronic ailments are becoming more common. Since 1970, China's population life span has grown by 17 years. From 2010 to 2040, the proportion of Chinese citizens aged 60 and up is expected to rise from 12.4% (168 million) to 28% (402 million).
According to WHO, Diabetes affects over 10% of all adults in China, or around 110 million individuals. Diabetes and its consequences account for about 1 million deaths in China each year. Rising incidence of chronic illnesses, technical improvements, and the expansion of the biologics industry leads to the increasing demand for drug delivery devices.
The research report finds that the COVID-19 pandemic short term impact on China drug delivery market, due to supply chain disruptions and delay in elective procedures. Drug delivery systems are being used more frequently to improve patient health and treatment outcomes, as post-pandemic chronic diseases become more prevalent. For instance,
- In September 2022, the International Diabetes Federation's Diabetes Atlas 2021 reports that there were 140.8 million diabetics in China and this number is expected to rise to 164 million by 2030.
The incidence of diabetes in China is gradually increasing, which is expected to drive demand for prefilled syringes and autoinjectors in the coming years. Rising incidence of cardiovascular illnesses (CVD) increase the use of long-term medication. Increasing awareness regarding novel drugs among population is anticipated to boost the market.
Impact of Artificial Intelligence in the China Drug Delivery Devices Market
Traditional Chinese Medicine (TCM) has been used for hundreds of years in China to prevent and treat various ailments. Increased awareness among population for novel drug therapies paved the way for technological advancements. Integration of Artificial Intelligence (AI) in drug delivery system help patients to manage their medication in better way.
AI algorithms analyze patient data to provide personalized recommendations for medication management. It is particularly helpful for patients with diabetes to manage their condition effectively. AI provides real-time assistance in managing blood sugar levels and helps users gain insights into their glucose patterns, which in turn, assists in making informed decisions about diet and lifestyle choices.
China Drug Delivery Devices Market Dynamics
Major Drivers
Development in novel drugs and delivery system is expected to drive market during the forecast period, as advancements in technology increases the simplicity of the device and make it possible to be administrated by the patient directly. Moreover, rising obesity and diabetes among the urban population leading to heart related issue is the major driver for the China drug delivery devices market.
Existing Restraints
Unaffordability, lack of or no reimbursements are anticipated to restrain the market growth during the forecast period. Risk of needlestick injuries is projected to hamper the market expansion. Moreover, the high cost of development for drug delivery devices is expected to hinder the market.
Emerging Opportunities
Development in new generation devices such as portable and wearable are gaining popularity particularly in the home healthcare and is anticipated to create lucrative opportunities for market players. Wearable technology, also known as "wearables," include Continuous Glucose Monitoring (CGM) devices, fitness trackers, smartwatches, and smart technology clothing, all of which provides real-time monitoring to individuals to manage their health and wellness.
Scope of the China Drug Delivery Devices Market Report
The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics have also been included in the report.
| Attributes |
Details |
| Report Title |
China Drug Delivery Devices Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
| Base Year |
2022 |
| Historic Data |
2016–2021 |
| Forecast Period |
2023–2031 |
| Segmentation |
Route of Administration (Oral, Injectable, and Transdermal), Device Type (Implantable, Nasal [Inhalers and Others], Injectable [Self-injectable Drug Delivery Devices {Auto-injectors, Prefilled Syringes, Other Self-injectables Drug Delivery Devices} and Conventional Drug Delivery Devices], and Others), Application (Cardiovascular, Diabetes, Oncology, Autoimmune Disorder, Pulmonary Disease, and Other), and End-user (Hospitals, Pharmacy, and Others) |
| Country Scope |
China |
| Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast |
| Key Players Covered in the Report |
Becton; Dickinson and Company; F. Hoffmann-La Roche AG; Gerresheimer AG; Pfizer Inc.; and Teva Pharmaceutical Industries Ltd. |
China Drug Delivery Devices Market Segment Insights
Route of Administration Segment Analysis
Based on route of administration, China drug delivery devices market share is divided into oral, injectable, and transdermal. The oral segment is expected to hold a significant share of the market in the coming years. Wide range of dosage forms comes under oral drug delivery products such as capsules, tablets, syrups, solutions, films, and suspensions.
Oral route of administration is considered safe and preferred due to cost, drug stability, and comfortable to use. Inhalation drug delivery systems are widely used in case of pulmonary conditions including Chronic Obstructive Pulmonary Disease (COPD) and asthma.
Inhalation drug delivery system is widely used in cases of pulmonary conditions including Chronic Obstructive Pulmonary Disease (COPD) and asthma. Rising prevalence of poof respiratory diseases and technological advancement of devices used for inhalation delivery including inhalers and nebulizers are projected to propel the segment growth.
The injectables segment accounts for a considerable market share, due to the rising technological advancements in drug delivery systems. The advancements in injectables such as prefilled syringes, pen injectors, and wearable injectors increased the demand for injectable drug delivery systems. Moreover, the segment growth is driven by the development of materials for syringes such as polymers, which are inert to most chemicals.
Device Type Segment Analysis
In terms of device type, the China drug delivery devices market share is segmented into implantable, nasal, injectable and others. The nasal segment is further bifurcated into inhalers and others. The injectable segment is further bifurcated into self-injectable drug delivery devices and conventional drug delivery devices.
The self-injectable drug delivery devices segment is further categorized as auto-injectors, prefilled syringes, other self-injectables drug delivery devices. The nasal segment is anticipated to expand at a substantial CAGR during the forecast period, due to the rising product launches by market players and prevalence of chronic diseases. For instance,
-
In August 2021, Oyster Point Pharma recently sold the rights to two nasal sprays, designed for patients with dry eye disease in China to Ji Xing Pharmaceuticals for USD 17.5 million upfront. This deal took place before the FDA’s upcoming decision, which is anticipated to make one of these drugs the first-ever nasal spray approved for treating dry eye disease.
The injectable segment is expected to hold a significant share of the market, owing to the research and development activities and collaborations and partnerships among market players. The research and development activities help to create advance products such as auto-injectors. Autoinjectors are easy to use and convenient for treating chronic diseases and is anticipated to boost the segment in the coming years.
Application Segment Analysis
On the basis of application, the market is segregated into cardiovascular, diabetes, oncology, autoimmune disorder, pulmonary disease, and other. The oncology segment is anticipated to expand at a substantial CAGR during the forecast period, due to the rising prevalence of cancer. Two types of drug delivery systems widely used in oncology includes albumin and liposomal nanoparticle drug delivery devices.
The pulmonary disease segment is expected to hold a significant share of the market, owing to rising demand for the drug delivery devices in the country. Pulmonary drug devices are helpful in inhaling medicine through the mouth and depositing it in the lower airways. Technological advancements in the drug delivery devices are anticipated to increase its demand for management of disease.
End-user Segment Analysis
Based on end-user, the market is segmented into hospitals, pharmacy, and others. The hospitals segment is projected to register considerable share of the market in the coming years, due to the rising cases of neurological disorders, diabetes, and cancer. Different patients admitted to hospitals with various disorders require different drugs for treatment, and for this purpose, different drug delivery devices are used.
The others segment is expected to hold substantial CAGR during the forecast period. Rising trend of self-administration and increased treatments in home care settings compared to hospitals is expected to boost the segment. Moreover, diagnostic center is actively working to develop and adopt novel drug delivery devices that accurately deliver drugs.
Segments
The China drug delivery devices market has been segmented on the basis of
Route of Administration
- Oral
- Injectable
- Transdermal
Device Type
- Implantable
- Nasal
- Injectable
- Self-injectable Drug Delivery Devices
- Auto-injectors
- Prefilled Syringes
- Other Self-injectables Drug Delivery Devices
- Conventional Drug Delivery Devices
- Others
Application
- Cardiovascular
- Diabetes
- Oncology
- Autoimmune Disorder
- Pulmonary Disease
- Other
End-user
- Hospitals
- Pharmacy
- Others
Country
Key Players
Competitive Landscape
Key players competing in the China drug delivery devices market include F. Hoffmann-La Roche AG; Becton; Dickinson and Company; Teva Pharmaceutical Industries Ltd.; Gerresheimer AG; Pfizer Inc. Several key players are competing in the drug delivery devices market in China to strengthen their geographical presence, these players engage in mergers and acquisitions, collaborations, agreements, and partnerships.
- In November 2022, DKSH and Nuance Pharma have signed an agreement to introduce Hong Kong and Macau. This agreement aligns with DKSH Business Unit Healthcare's strategic focus of expanding into higher value-added segments and services, such as medical devices.
- In June 2022, OcuMension Therapeutics and EyePoint Pharmaceuticals, Inc. received approval from China's Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg to treat chronic non-infectious uveitis affecting the posterior segment of the eye.
Request For Customization
Enquiry Before Buying
Speak With Analyst
